Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, patients with alopecia areata were found to have significantly lower serum zinc levels compared to healthy controls, and lower zinc levels were associated with more severe disease.

This review analyzed data on alopecia types associated with COVID-19, suggesting androgenetic alopecia may be a risk factor for severe COVID-19, while telogen effluvium often follows infection and alopecia areata tends to relapse in those with preexisting disease.

This study found that 64.8% of patients with different types of alopecia had vitamin D deficiency, and those with lichen planopilaris and telogen effluvium had higher odds of severe deficiency compared to patients with alopecia areata.

This review highlights the connection between sex hormones and metabolic dysfunction, emphasizing how conditions like male hypogonadism and female hyperandrogenism can increase the risk and severity of hepatic steatosis, which often progresses alongside metabolic syndrome and elevates mortality risks.

This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.

This study found that the MIR34A rs2666433 (A/G) variant is linked to increased risk and severity of alopecia areata, and high circulatory miR-34a levels may play a role in the disease's pathogenesis.

This review compiles current insights into alopecia areata's epidemiology, immune mechanisms, diagnosis, treatment options, including novel JAK inhibitors, and its severe psychosocial impact, while also highlighting emerging research areas.

This review discusses the efficacy, safety, and practical aspects of using Janus kinase inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—as treatments for severe alopecia areata in an advanced practice provider context, without reporting specific study results.

This systematic review concluded that oral JAK inhibitors, such as baricitinib and deuruxolitinib, are effective and generally well-tolerated treatments for moderate-to-severe alopecia areata, offering advantages over traditional therapies.

Alopecia areata incognito in children can be effectively treated with triamcinolone acetonide and supplements, leading to full hair regrowth.

This study reports the first case of mandibuloacral dysplasia syndrome associated with MTX2 gene mutation in the Chinese population, expanding the known spectrum of MTX2 mutations.

This overview discusses the condition and treatments for alopecia areata, highlighting that the JAK inhibitor baricitinib, recently approved for severe cases, shows unprecedented effectiveness but raises cost and risk debates regarding treatment of this primarily cosmetic autoimmune disorder.

This study found that individuals with alopecia areata had significantly lower vitamin D levels compared to healthy controls, and lower vitamin D levels were associated with more severe hair loss.

This study found that Chinese patients with alopecia totalis or universalis had an earlier onset, longer disease duration, and more severe quality of life impact compared to those with patchy alopecia areata.

This study found that among Chinese patients with alopecia areata, those with alopecia totalis/universalis had an earlier onset, longer duration, and more severe quality of life impact compared to those with patchy alopecia.

This study observed that Chinese patients with alopecia totalis or universalis had an earlier onset, longer duration, and more severe impact on quality of life compared to those with patchy alopecia areata.

This study found that Prss53-mutated rabbits exhibited curved hair and skeletal dyskinesia, suggesting a link between Prss53 loss and these traits, potentially involving disrupted calcium metabolism.

This study presented two cases of chronic hypervitaminosis A in adults, highlighting the first reported instance of hepatic cirrhosis due to long-term beef liver consumption.

This case report describes a woman experiencing severe hair loss due to allergic contact dermatitis from a hair dye containing PPD.

This article discusses the uncertainty regarding distinct skin findings and cardiometabolic profiles among PCOS subtypes and reports no new clinical data.

This analysis explores possible causes of menstrual irregularities in women with PCOS following COVID-19, but reports no new clinical findings.

This review discusses the substantial impact of alopecia areata on patients' health-related quality of life, highlighting issues such as personality changes, emotional and social difficulties, and a common occurrence of alexithymia, and emphasizes the need for more specific assessment tools.

This study suggests that off-label use of baricitinib in children under 12 with alopecia areata may improve hair regrowth, but further research is needed to confirm efficacy and safety.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

This study found that oral tofacitinib monotherapy improved nail changes in 73.3% of adults with moderate-to-severe alopecia areata over a median period of 5 months, but nail improvement was not linked to the severity of hair loss or hair regrowth.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

This review suggests that 308 nm excimer therapy may offer a well-tolerated non-pharmacologic option for alopecia areata, with more limited evidence for its effectiveness in lichen planopilaris and frontal fibrosing alopecia.

This study found that among various JAK inhibitors for severe alopecia areata, baricitinib_4 mg demonstrated significant efficacy with high precision, while deuruxolitinib_12 mg showed the best efficacy but with wider confidence intervals, providing clinicians valuable information for treatment selection.

In this study at Tohoku University Hospital, 41% of severe alopecia areata patients achieved significant hair regrowth with baricitinib treatment over 9 months, with predictors of better outcomes including shorter disease duration, female sex, initial mild disease, certain alopecia types, and prior IVMP therapy.